Bioassociate Consulting
Long/short equity, value, event-driven, long only

BioLine Is Approaching Its Moment Of Truth

BioLineRx (NASDAQ:BLRX) is about to face one of its defining moments in 1Q 2013, when results of an interim analysis from the phase 2/3 CLARITY study of BL-1020 are expected to be released. BL-1020, BioLine's leading drug candidate, is an orally available GABA-enhanced antipsychotic for the treatment of both the positive and cognitive effects of schizophrenia. The cognitive impairment associated with schizophrenia (OTC:CIAS), which is less recognized than the positive effects of the condition (reasonably treated by current antipsychotics), is exhibited as deterioration of long-term memory, concentration and ability to perform executive functions. CIAS affects the vast majority of schizophrenia patients and severely damages their overall functional and quality of life outcomes.

We think that the...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details